NEMUS BIOSCIENCE INCORPORATED (OTCMKTS:NMUS) on Focus After Report of Less Shorts

July 18, 2017 - By Clifton Ray

The stock of NEMUS BIOSCIENCE INCORPORATED (OTCMKTS:NMUS) registered a decrease of 11.78% in short interest. NMUS’s total short interest was 35,200 shares in July as published by FINRA. Its down 11.78% from 39,900 shares, reported previously. With 128,600 shares average volume, it will take short sellers 0 days to cover their NMUS’s short positions.

The stock increased 1.85% or $0.005 on July 17, reaching $0.275. About 35,980 shares traded. Nemus Bioscience Inc (OTCMKTS:NMUS) has 0.00% since July 18, 2016 and is . It has underperformed by 16.70% the S&P500.

Nemus Bioscience, Inc. is a biopharmaceutical company. The company has market cap of $7.94 million. The Firm is focused on the discovery, development and the commercialization of cannabinoid therapeutics through its partnership with the University of Mississippi . It currently has negative earnings. It is UM’s partner for the development and commercialization of drugs derived from cannabis extracts, or cannabinoids.

More notable recent Nemus Bioscience Inc (OTCMKTS:NMUS) news were published by: Multiplesclerosisnewstoday.com which released: “Leading Developer Of Cannabis-Based Therapeutics Nemus To Address MS, Other …” on February 09, 2015, also Seekingalpha.com with their article: “A Sit Down With Nemus Bioscience; Cannabinoids In Focus” published on February 01, 2017, Streetinsider.com published: “Form 424B3 Nemus Bioscience, Inc.” on July 11, 2017. More interesting news about Nemus Bioscience Inc (OTCMKTS:NMUS) were released by: Seekingalpha.com and their article: “NEMUS Bioscience: A Unique Approach To The 32 Million Rx US Glaucoma Market” published on May 15, 2015 as well as Seekingalpha.com‘s news article titled: “Is Nemus Bioscience An Investment Opportunity In The Cannabis Space?” with publication date: June 01, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: